Review in NMR in biomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors at 2 institutions in 1 country.
Alexander A ShestovPerelman School of Medicine, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Kavindra NathPerelman School of Medicine, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
David S NelsonPerelman School of Medicine, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Mariusz A WasikDepartment of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Jerry D GlicksonPerelman School of Medicine, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
University of Pennsylvania · USFox Chase Cancer Center · US
Funding
Metabolic Imaging of Targeted Therapies in CancerR01CA268601 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Kavindra Nath, MARIUSZ A. WASIK · 2022 to 2026
$3.0M
Metabolic Biomarkers of Response of Mantle Cell Lymphoma to Bruton Tyrosine Kinase InhibitionR01CA228457 · NCI · UNIVERSITY OF PENNSYLVANIA · PI NATH, KAVINDRA, WASIK, MARIUSZ A. · 2020 to 2024
$2.5M
Melanoma: Metabolic Biomarkers of Response to Targeted TherapyR01CA250102 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BLAIR, IAN ALEXANDER, NATH, KAVINDRA · 2020 to 2024
$2.4M
Translation of Noninvasive Metabolic Biomarkers to Targeted Therapy for CancerR21CA280523 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ARIAS-MENDOZA, FERNANDO, NATH, KAVINDRA · 2024 to 2025
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Bonded cumomer analysis of tumor metabolism based on · full record | Socratic